



香港中文大學醫學院
Faculty of Medicine
The Chinese University of Hong Kong

Engineered Bacteria for Medical Use

Supervisor: Dr. Xiao Yang


Tsz Fung Tsang, Peter (Yr. 1 MPhil student)

14/12/2018

Microbiology

Genetically Modified Organisms (GMOs) emerged from gene engineering

- ▶ Definition: Organisms in which the genetic material (DNA) has been altered in a way that does not occur naturally by mating and / or natural recombination.




Innovation: Using GMOs as therapeutics / diagnostics

GMOs facilitate drug delivery


1. For drug molecules of short half-lives
 - ▶ The effector is synthesised after reaching the target site
2. Reaching target therapeutic sites directly
 - ▶ The treatment can be localised without severe systemic side-effect

Engineered bacteria works by releasing effectors in specific regions




1. Releases molecules in the gut

Engineered bacteria works by releasing effectors in specific regions




2. Releases toxin, triggers immunity against tumours



The specificity is achieved by coupling quorum-sensing with recombinant gene expressions

Engineered bacteria can stimulate immune response




3. Expresses antigens found in tumour

Harmless bacteria to be selected

- ▶ Should be easy in genetic manipulation and can be grown rapidly
- ▶ Should cater to the target sites (the gut, mouth)
- ▶ Shouldn't be colonised in humans (*L. lactis* eliminated from human body in approximately 3 days)
- ▶ For oral delivery to the gut: *Lactococcus lactis* and *Escherichia coli*

L. lactis as the first bacteria in practice

- ▶ *L. lactis* is well known as food bacteria in milk fermentation
- ▶ GRAS status (generally recognized as safe) by FDA



http://textbookofbacteriology.net/featured_microeb.html

Other factors making it suitable for genetic manipulation

- ▶ Well studied gene expression system
- ▶ Tendency to secrete recombinant protein
- ▶ Only one constitutively expressed protease



Examples of *L. lactis* engineering

1. Detection of cholera in mouse model
2. Expression of IL-10 in mouse model with asthma

CAI-1 detection in mice infected with cholera

- ▶ Cholera is a disease mainly caused by poor water quality, resulting in severe dehydration and even death
- ▶ No *in vivo* cost-effective method in detection
- ▶ New detection assay developed based on GMOs
 - ▶ CAI-1: quorum-sensing molecules from *Vibrio cholerae*
 - ▶ *L. lactis* was modified to express hybrid receptor for CAI-1, binding of CAI-1 triggers reporter β -lactamase synthesis

CAI-1 detection by β -lactamase reporter assay



Colour development within 30 mins

Intragastric inoculation and collection of stool samples

No positive signal from healthy individual and infection by mutant *V. cholerae* : **CAI-1 specific**


Examples of *L. lactis* engineering

1. Detection of cholera in mouse model
2. **Expression of IL-10 in mouse model with asthma**

Delivery of IL-10 in mice with asthma


- ▶ Asthma is characterised by acute inflammation in lungs, constriction of airways
 - ▶ 300 million people suffer from it
- ▶ Eosinophil is an essential modulator in lung inflammation
- ▶ IL-10: cytokine synthesis inhibitory factor, potent inhibitor of eosinophil
- ▶ *L. lactis* expressing IL-10 was made and intranasal administration was done in mice with ovalbumin-induced acute airway inflammation

Recombinant IL-10 was successfully synthesised and suppressed eosinophil level



Amount of IL-10 in control and samples


LL-CYT: IL-10 in cytoplasmic form
LL-SEC: IL-10 in secreted form



Eosinophil amount

OVA: asthma induction

Recombinant IL-10 reduced OVA-specific IgE level



OVA: asthma induction

LL-CYT: IL-10 in cytoplasmic form


LL-SEC: IL-10 in secreted form

Concerns about the biological safety

1. Spreading outside lab
2. Unknown interaction between microbes
 - ▶ e.g. DNA sharing between microbes
 - ▶ The recombinant proteins may be overproduced by modified bacteria and residential gut microbes


Cell death by *thyA* gene deletion

- ▶ In modified *L. lactis*, the thymidylate synthase gene *thyA* was replaced with recombinant genes



Cell culture in thymidine-free medium

MG1363: Wild type
Thy12: *L. lactis* without *thyA* gene



L. lactis detection from pig

No acquisition of foreign *thyA* gene observed

- ▶ The research teams tried mixing modified and wild type *L. lactis* during cell growth
 - ▶ No isolation of modified *L. lactis* showing thymidine-independent growth
 - ▶ Possible reason: diversity in *thyA* gene sequences

The functional stability may not be high

- ▶ Longer duration of bacteria in body, higher possibility for mutations to happen
 - ▶ The insertion of foreign genes reduces growth rate
 - ▶ The microenvironment in body may be competitive (less oxygen / nutrient)
 - ▶ Provides selective pressure (point mutation / loss of function)
- ▶ Resulted in 50% loss of cells carrying desired plasmids in some studies

The expression condition is not optimal in practice

- ▶ *In vitro* protein synthesis always done in optimal conditions (full of nutrients, rich in oxygen)
- ▶ Reality: The nutrient and oxygen are limited, lowering expression level and ultimately limiting cell growth

Summary

- ▶ GMOs can be useful in treating disease
- ▶ Aside from drug delivery, GMOs can also be used as diagnostic tools
- ▶ Stability and safety problems have to be addressed before application in real-world settings

Thank you very much for your kind attention

References

Ceroni, F., Furini, S., Gorochofski, T. E., Boo, A., Borkowski, O., Ladak, Y. N., . . . Ellis, T. (2017). Burden-driven feedback control of gene expression. *bioRxiv*. doi:10.1101/177030

Danino, T., Prindle, A., Hasty, J., & Bhatia, S. (2013). Measuring Growth and Gene Expression Dynamics of Tumor-Targeted *S. Typhimurium* Bacteria. *Journal of Visualized Experiments*, (77). doi:10.3791/50540

From Corgis to Corn: A Brief Look at the Long History of GMO Technology. (2016, October 23). Retrieved from <http://sitn.hms.harvard.edu/flash/2015/from-corgis-to-corn-a-brief-look-at-the-long-history-of-gmo-technology/>

Landry, B. P., & Tabor, J. J. (2017). Engineering Diagnostic and Therapeutic Gut Bacteria. *Microbiology Spectrum*, 5(5). doi:10.1128/microbiolspec.bad-0020-2017

Mao, N., Cubillos-Ruiz, A., Cameron, D. E., & Collins, J. J. (2018). Probiotic strains detect and suppress cholera in mice. *Science Translational Medicine*, 10(445). doi:10.1126/scitranslmed.aao2586

Marinho, F. A., Pacífico, L. G., Miyoshi, A., Azevedo, V., Loir, Y. L., Guimarães, V. D., . . . Oliveira, S. C. (2010). An intranasal administration of *Lactococcus lactis* strains expressing recombinant interleukin-10 modulates acute allergic airway inflammation in a murine model. *Clinical & Experimental Allergy*, 40(10), 1541-1551. doi:10.1111/j.1365-2222.2010.03502.x

Reardon, S. (2018). Genetically modified bacteria enlisted in fight against disease. *Nature*, 558(7711), 497-498. doi:10.1038/d41586-018-05476-4

Song, A. A., In, L. L., Lim, S. H., & Rahim, R. A. (2017). Erratum to: A review on *Lactococcus lactis*: From food to factory. *Microbial Cell Factories*, 16(1). doi:10.1186/s12934-017-0754-1

Steidler, L., Neiryck, S., Huyghebaert, N., Snoeck, V., Vermeire, A., Goddeeris, B., . . . Remaut, E. (2003). Biological containment of genetically modified *Lactococcus lactis* for intestinal delivery of human interleukin 10. *Nature Biotechnology*, 21(7), 785-789. doi:10.1038/nbt840